Teijin Carbon Europe GmbH, the Teijin Group’s carbon fiber business in Europe, has increased the production capacity of its German produced chopped carbon fiber type Tenax®-E HT C604 6mm by 40 %. The company is thus responding to the growing demand by European electronics manufacturers in recent years, as well as to currently increasing needs for compounds for medical devices.
The success of the German chopped product C604 is based on its excellent quality, enabling the production of high-grade compounds (plastic granulate reinforced with car- bon fiber) with superior mechanical properties and good electrical conductivity.
Demand for C604 has increased significantly in recent years. So far, demand of Euro- pean customers has partly been satisfied by delivering the same product type produced at Teijin’s Mishima plant in Japan. With the increased German capacity, Teijin can now react more flexible to inquiries in the European market.
Other product types of Tenax® short fiber – chopped, pelletized or milled – are produced at facilities in Japan and the US. They are supplied in a variety of sizings to be used, besides thermoplastic materials, with thermosets and in water-based processes.
Teijin is further strengthening the development of its carbon fiber product portfolio and aims to be a company that supports the society of the future by delivering innovative high-performance materials and solutions with real value.
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan’s first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fi- bers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equip- ment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital enter- tainment. Deeply committed to its stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions”, Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY
853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2020.